| Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus R Shechter, O Miller, G Yovel, N Rosenzweig, A London, J Ruckh, ... Immunity 38 (3), 555-569, 2013 | 721 | 2013 |
| Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer’s disease pathology K Baruch, N Rosenzweig, A Kertser, A Deczkowska, AM Sharif, A Spinrad, ... Nature communications 6 (1), 7967, 2015 | 455 | 2015 |
| PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease K Baruch, A Deczkowska, N Rosenzweig, A Tsitsou-Kampeli, AM Sharif, ... Nature medicine 22 (2), 135-137, 2016 | 380 | 2016 |
| IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair G Kunis, K Baruch, N Rosenzweig, A Kertser, O Miller, T Berkutzki, ... Brain 136 (11), 3427-3440, 2013 | 342 | 2013 |
| Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner A Deczkowska, O Matcovitch-Natan, A Tsitsou-Kampeli, S Ben-Hamo, ... Nature communications 8 (1), 717, 2017 | 218 | 2017 |
| PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model N Rosenzweig, R Dvir-Szternfeld, A Tsitsou-Kampeli, H Keren-Shaul, ... Nature communications 10 (1), 465, 2019 | 150 | 2019 |
| Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,394,365, 2016 | 47 | 2016 |
| Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,856,318, 2018 | 44 | 2018 |
| APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints Z Yin, N Rosenzweig, KL Kleemann, X Zhang, W Brandão, MA Margeta, ... Nature immunology 24 (11), 1839-1853, 2023 | 43 | 2023 |
| Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 10,214,585, 2019 | 31 | 2019 |
| Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 10,144,778, 2018 | 31 | 2018 |
| Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 10,519,237, 2019 | 29 | 2019 |
| Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,512,225, 2016 | 22 | 2016 |
| Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,534,052, 2017 | 20 | 2017 |
| Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,512,227, 2016 | 20 | 2016 |
| Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 10,618,963, 2020 | 15 | 2020 |
| Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,982,051, 2018 | 11 | 2018 |
| Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,982,049, 2018 | 11 | 2018 |
| Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,982,047, 2018 | 11 | 2018 |
| Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease M Eisenbach-Schwartz, K Baruch, N Rosenzweig US Patent 9,982,050, 2018 | 11 | 2018 |
